Brooke McCormick

In patients with NSCLC, 3+1 lymph node sampling was not linked to higher postoperative complications, supporting guideline adherence.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Men and urban minority patients with early-onset CRC face elevated CVD death risk, highlighting gaps in survivorship care and research, Meng-Han Tsai, PhD, said.

Structural racism was associated with wider NSCLC survival disparities, with a 10-point Black-White gap in highly segregated counties.

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.

Girls and young women, as well as older teens, were more likely to report AI chatbot use for mental health advice, with Black youth more likely to engage monthly.

Children aged 2 to 5 years with fall birthdays had higher flu vaccination rates and fewer diagnoses than those with summer birthdays.

Early-onset CRC CVD mortality disparities highlight the need for integrated data and risk-based survivorship care, said Meng-Han Tsai, PhD.

Durvalumab plus BCG also marks the first new treatment in more than 30 years for high-risk non–muscle-invasive bladder cancer.

Health plan infrastructure and patient reporting are underutilized, powerful tools for identifying food insecurity, Jonathan Wrathall, PhD, argues.

A population study finds familial melanoma gene variants are more common than thought, linking them to a higher risk of multiple cancers beyond melanoma.

ACS updated CRC screening guidelines, adding blood-based and stool tests to expand screening access and improve early detection.

Jonathan Wrathall, PhD, explains that his 2 studies found social needs and insurance type strongly predicted food insecurity.

A study led by Meng-Han Tsai, PhD, found that men and racial and ethnic minority patients with early-onset CRC in urban areas face a higher CVD death risk.

Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about rural disparities.

Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs.

Kirk Campbell, MD, sees sparsentan as the beginning of a new treatment era for FSGS, a condition that has lacked approved therapies until now.

Investigators found major variation in prior authorization rules across commercial insurers, highlighting limited standardization and transparency.

ALIS plus MDT improved symptoms and culture conversion in newly diagnosed MACLD, according to late-breaking data presented at ATS 2026.

A cross-sectional analysis found diverging skin cancer trends by region, with basal cell carcinoma projected to have the highest global burden by 2050.

Text message reminders increased CRC screening completion at 2 FQHCs, with the strongest impact seen for Cologuard use.

Older adults with prior adenomas had slightly higher CRC risk, but 10-year CRC incidence was far outweighed by non-CRC mortality, supporting reduced surveillance colonoscopy use.

Skin cancers arising from burn scars carry high recurrence and mortality risks, with squamous cell carcinoma considered most common.

Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.

Circulating tumor DNA (ctDNA) detection is linked to worse survival outcomes in resectable melanoma, but high false-negative rates limit its use in surveillance or de-escalation.

Younger patients with early-onset CRC, especially men and racial and ethnic minority groups in urban areas, face a higher risk of cardiovascular death.

In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to equitable access.

Deborah Doroshow, MD, PhD, blends oncology and history of medicine to guide cancer care, emphasizing communication, trust, and health equity.

Deborah Doroshow, MD, PhD, an oncologist and historian, reflects on guiding patients through cancer care and how lessons from the past shape treatment today.